On Friday, H.C. Wainwright maintained a Buy rating and a $23.00 price target on shares of Nkarta Inc. (NASDAQ:NKTX), following the company's announcement of the commencement of patient screening in its Ntrust-1 study. The study is evaluating NKX019, a treatment for refractory lymphoma (LN), across multiple centers.
The Ntrust-1 study is set to initially enroll 12 patients to assess the efficacy of a three-dose cycle of NKX019, administered at 1B or 1.5B cells per dose on Days 0, 7, and 14, following a single-agent lymphodepletion with cyclophosphamide (Cy). The trial's design includes the possibility of a dose expansion study, contingent on the early data aligning with results observed by competitors to date.
Nkarta has indicated that initial data from the study is expected to be available in 2025, with projections suggesting it could emerge in the first half of the year. The analyst from H.C. Wainwright has noted the potential for NKX019 to offer several advantages over competing treatments, including a better safety profile with potentially lower rates of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Additionally, NKX019's allogeneic nature, as opposed to the autologous KYV-101 from Kyverna, could represent a point of differentiation.
Furthermore, the analyst highlighted the less burdensome lymphodepletion regimen of Cy alone used in NKX019's trial, compared to the Flu/Cy regimen for KYV-101. The potential for re-treatment with NKX019, which could lead to a longer duration of remission, was also noted as a positive aspect of the treatment.
The Buy rating and $23.00 price target reiteration by H.C. Wainwright reflect the firm's optimism about the prospects of NKX019 and its potential impact on the treatment of refractory lymphoma.
In other recent news, Nkarta, Inc. has initiated patient screening for its first U.S. clinical trial, Ntrust-1, for NKX019, a cell therapy aimed at treating lupus nephritis. The company also received FDA clearance for Ntrust-2, another trial for NKX019, targeting systemic sclerosis, myositis, and vasculitis. Concurrently, Nkarta has added Dr. George Vratsanos, an expert in translational immunology, to its board of directors, following the announcement of its fourth-quarter earnings for 2023 and a successful $240 million public offering.
The funds raised are expected to be used for the development of NKX019. In response to these developments, analyst firms Canaccord Genuity and Mizuho Securities maintained a Buy rating, while Raymond James downgraded the stock from a Strong Buy to an Outperform rating.
Clinical data from both Ntrust-1 and Ntrust-2 trials are anticipated in 2025. These trials are built on previous academic research demonstrating the potential for durable, drug-free remissions in autoimmune diseases following CD19-targeted cell therapy.
InvestingPro Insights
As Nkarta Inc. (NASDAQ:NKTX) advances its Ntrust-1 study, investors and analysts are closely monitoring the company's financial health and stock performance. According to InvestingPro Data, Nkarta holds a market capitalization of $412.94 million, suggesting a moderate level of investor interest in the biotech space. The company's current Price to Book ratio stands at 0.87, indicating that the stock may be undervalued relative to the company's net assets as of the last twelve months ending Q1 2024.
InvestingPro Tips for Nkarta reveal a mixed financial landscape. On the positive side, the company holds more cash than debt on its balance sheet and has liquid assets that exceed short-term obligations. These factors suggest a degree of financial stability, which could be reassuring to investors considering the inherent risks of biotech investments. On the other hand, Nkarta is quickly burning through cash and suffers from weak gross profit margins. Additionally, analysts do not anticipate the company will be profitable this year, and the price has fallen significantly over the last three months, with a 45.79% drop in total return. Despite these challenges, Nkarta has experienced a high return over the last year, with a 136.29% increase in price total return, demonstrating the stock's volatility and potential for high returns.
For investors seeking a deeper analysis, there are additional InvestingPro Tips available, which can be accessed at Investing.com/pro/NKTX. Utilizing the exclusive coupon code PRONEWS24, readers can receive an additional 10% off a yearly or biyearly Pro and Pro+ subscription, gaining access to a broader range of insights and data to inform their investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.